Top Tech Companies (51)
Terremoto Biosciences is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications.
Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead.
At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes. We do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality. Over the last 15 years, the fields of genomics and transcriptomics have undergone an explosion in content and discovery, fueled by massively parallel technologies that made large-scale studies possible and tractable. Advancement in those fields have deepened our understanding of biology and ushered in new treatment mechanisms and diagnostics solutions that impact everyday human life. Similar capabilities have evaded the field of proteomics. As a result, researchers have been forced into a tradeoff: the scale of the study, or the depth of its coverage. Until now. We’re committed to eliminating the obstacles that have kept proteomics’ potential from matching the pace of advancements we’ve seen in other fields. We believe that unbiased, deep, rapid, large-scale proteomics can, and must, become accessible to the broad scientific community so that we may significantly advance our understanding of biology, health, and disease. And those studies will require solutions that allow us to accurately survey and analyze the full diversity of proteins across individuals, over time.
Clone phishing is actually a subtype of phishing in which a cyber thief establishes an imitation of a genuine email. An original link or attachment is changed for a targeted one by the attacker, so the recipient will open it. As much as this method relies on trust, one needs to check the emails before having anything to do with them.
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Pivot Bio is the leading nitrogen innovator providing farmers and the world with a better nitrogen for improved productivity and sustainability. Learn how you can join the Pivot Bio team today and help us create a better tomorrow at pivotbio.com/careers.
By harnessing the power of genetics and technology, Invitae’s (“in-VEE-tay”) mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. We have helped improve care for hundreds of thousands of patients and their providers by driving down the cost of reliable, comprehensive, and actionable genetic testing. Our platform provides genetic information for use throughout medicine—and throughout life.
AllStripes’ mission is to unlock new treatments for people with rare disease. About 1 in 10 people have a rare disease, and half are children. AllStripes (formerly RDMD) was co-founded in 2017 by CEO Nancy Yu and Onno Faber, a rare disease patient deeply frustrated by the drug development process. “I was diagnosed with a rare genetic disease and it completely changed my perspective,” Onno shares. “Patients can’t be bystanders in drug development.” As the first and only research platform dedicated to rare diseases, AllStripes makes it easy for patients to contribute to new treatment studies from home. We do the work to collect and analyze your de-identified medical records to help power faster, better drug development for your condition. The name AllStripes was inspired by the official symbol for the rare disease community, the zebra. When we come together and learn from each other’s experiences we can push for better treatments across all rare conditions.
TeselaGen's artificial Intelligence powered platform radically accelerates product development of therapeutics, high value chemicals, and agricultural products. We are located in the software hub of San Francisco, California.
all.health has developed a comprehensive preventative and proactive healthcare platform that combines clinical-grade sensors, machine learning, patient histories, insurance claims data, and other information to provide real-time at-risk screening for several disease conditions; these include acute respiratory infections such as COVID-19, and chronic conditions such as hypertension and diabetes. Contextualized 24/7 data along with clinician input and interventions will then be used to guide positive behavior changes. The premise is to catch various health conditions early and help reverse or manage the negative effects.
